Admission Shock Index Is an Independent Predictor of In-Hospital All-Cause Mortality in Patients With Acute Aortic Dissection and Intramural Hematoma

入院休克指数是急性主动脉夹层合并壁内血肿患者院内全因死亡率的独立预测因子。

阅读:4

Abstract

BACKGROUND: Acute aortic dissection (AD) and intramural hematoma (IMH) are associated with high mortality, necessitating reliable early risk prediction. The shock index (SI) is a potential prognostic marker in critical care, but its value in AD/IMH remains unclear. This study evaluated the association between admission SI and in-hospital all-cause mortality. METHODS: This single-center retrospective cohort study included 1250 patients with acute AD/IMH, stratified by an optimal SI cut-off of 0.6 determined by ROC analysis. Kaplan-Meier curves and Cox proportional hazards models were used to assess the relationship. Subgroup analyses were also conducted to confirm the consistency of the main findings. RESULTS: The 30-day cumulative in-hospital all-cause mortality was significantly higher in the SI ≥ 0.6 group than in the SI < 0.6 group (Total: 25.7% vs. 14.4%, p < 0.001; Stanford A: 35.5% vs. 25.2%, p < 0.001; Stanford B: 13.4% vs. 4.8%, p < 0.001). An SI ≥ 0.6 was independently associated with increased in-hospital mortality (adjusted hazard ratio (aHR) 1.67, p = 0.004), consistent across Stanford A (aHR 1.52, p = 0.038) and Stanford B (aHR 2.57, p = 0.014) subgroups. Furthermore, the association was stronger among patients managed without surgery or thoracic endovascular aortic repair (TEVAR) (Total: aHR 2.02, p < 0.001; Stanford A: aHR 1.77, p = 0.009; Stanford B: aHR 3.30, p = 0.004). CONCLUSION: An admission SI ≥ 0.6 is independently associated with increased in-hospital all-cause mortality in acute AD/IMH, particularly among those managed without surgery/TEVAR. Admission SI may serve as a simple, rapid, and valuable tool for early clinical risk stratification.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。